TKMR since their secondary had to abandon their EBOLA vaccine, and they are purely a speculative play - nothing even in phase 1 in B Hep. BLUE on the other hand may have just cured sickle sell and beta-thal. Big difference.
once the secondary is closed with the 10$ over allotment taken, this will go back to 180+
George, I'm the first to hand it to you on your trade here. You made some $$$. I wouldn't let your trade linger, however.
If recent history repeats itself with most biotech secondaries on hot stocks over the past two years, , this will price in the 171-173.5 range, and then will be taken over $180-190 in short order, like in the next two weeks after it prices. Why? the price of the secondary establishes a new floor to valuation, as it tells existing holders that new and existing buyers of the secondary are willing to enter at this price with the expectation of going a lot higher. This isn't the case at all when a 'cold' company is bleeding cash and needs more desperately. But for a hot biotech like BLUE, watch out.
It doesn't. biotechpick is noting that in the treatment arm there was a thickening of the retina, which was one of the surprises in this data.
Wow I got that one wrong! Vision held and slightly improved, with fewer injections. Stock has tanked 60%. Obviously people are thinking that this will be relegated to a minor adjunct therapy in conjunction with Eylea or Lucentis, and not a replacement. Bottom line: the so-called gene therapy didn't work to cure anything here. There was clearly some efficacy, but on a commercial scale it's hard to see the economic return here.
...all of 10 months ago:
Receptos Up 8%; Wedbush Sees Possible Takeover
John Seward , Benzinga Staff Writer
August 25, 2014 4:43pm
Receptos RCPT 4.63% closed Monday just short of a 52-seek high after an analyst suggested the drug development company could become a takeover candidate.
Receptos is developing drugs for a range of immune system disorders including its lead product for multiple sclerosis and inflammatory bowel disease.
Wedbush's Liana Mousatos, who reiterated an Outperform rating and $63 target, said a conference slated for September 10 in Boston could become a venue for the company to unveil positive data from current drug trials.
Mousatos expects a Phase II trial of its treatment for inflammation of the esophagus to launch in the second half of 2014 along with release of interim results from a trial of its colitis drug.
Receptos closed Monday at $50.69, up 8.24 percent.
We've come a long way in a short time!
Sentiment: Strong Buy
I'm with you. This is a buyout if there ever was one. There are art least four companies licking their chops on this one. It's worth north of $11 billion, easy.
yes plus as soon as 1063 is approved it knocks Gilenya out of the water (better safety profile, possibly more effective), which is a 3 billion annual sales drug and growing.
At this point I'll take another look at OPHT. I may be done with eyes. I'm definitely done with AAV2 and AAV1 viral vectors.
rebel and magnam, ditto that. Cohen is famous for turning on a dime. Long 6 mill one day, short 6 mill the next. I think we've been watching Cohen's traders at work since he bought in. And I suspect nearly all of the movement today was compliments of Steve Cohen. As for J&J being down 30% Rebel, I think it's immaterial to them. As magnam is suggesting, I doubt seriously they give one whit about the market cap of ACHN, or the stock price, ever The $225 mill was the negotiated pay-to-play money at whatever premium in order to get at the crown jewels. JNJ trials are going to either make ACHN a penny stock or a $5 billion+ company.